Dex Liquidating (CRDC) 10-Q 10 Feb 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2016	Feb. 06, 2017
Document Information [Line Items]
Entity Registrant Name	DEXTERA SURGICAL INC
Entity Central Index Key	1,178,104
Trading Symbol	dxtr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		8,927,830
Document Type	10-Q
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 5,103	$ 3,626
Short-term investments	650	9,090
Accounts receivable, net	489	313
Inventories	1,505	1,063
Prepaid expenses and other current assets	108	318
Total current assets	7,855	14,410
Property and equipment, net	909	1,178
Restricted cash	104	104
Total assets	8,868	15,692
Current liabilities:
Accounts payable	1,000	766
Accrued compensation	582	739
Other accrued liabilities	391	517
Current portion of deferred revenue	633	569
Total current liabilities	2,606	2,591
Deferred revenue, net of current portion	2,384	2,499
Note payable, net of discount	3,293	3,124
Other non-current liabilities	167	196
Total liabilities	8,450	8,410
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.001 par value: 5,000,000 shares authorized; 191,474 shares issued and outstanding at December 31, 2016, and June 30, 2016	17,214	17,214
Common stock, $0.001 par value: 125,000,000 shares authorized; 8,934,452 shares issued and 8,927,830 shares outstanding at December 31, 2016, and June 30, 2016	9	9
Additional paid-in capital	197,079	196,355
Treasury stock at cost (6,622 shares at December 31, 2016, and June 30, 2016)	(596)	(596)
Accumulated comprehensive loss		(4)
Accumulated deficit	(213,288)	(205,696)
Total stockholders' equity	418	7,282
Total liabilities and stockholders' equity	$ 8,868	$ 15,692

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Dec. 31, 2016	Jun. 30, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	191,474	191,474
Preferred stock, shares outstanding (in shares)	191,474	191,474
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	8,934,452	8,927,830
Common stock, shares outstanding (in shares)	8,934,452	8,927,830
Treasury stock, shares acquired (in shares)	6,622	6,622

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands		3 Months Ended		6 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Net revenue:
Product sales, net		$ 695,000	$ 683,000	$ 1,122,000	$ 1,420,000
License and development revenue		83,000		109,000
Royalty revenue		21,000	17,000	35,000	35,000
Total net revenue		799,000	700,000	1,266,000	1,455,000
Operating costs and expenses:
Cost of product sales		940,000	889,000	1,455,000	1,912,000
Research and development		1,400,000	1,630,000	3,168,000	3,246,000
Selling, general and administrative		1,960,000	2,161,000	3,979,000	4,818,000
Total operating costs and expenses		4,300,000	4,680,000	8,602,000	9,976,000
Loss from operations		(3,501,000)	(3,980,000)	(7,336,000)	(8,521,000)
Interest income		7,000	14,000	21,000	27,000
Interest expense		(137,000)	(123,000)	(270,000)	(243,000)
Other income (expense), net		(6,000)	2,000	(7,000)	8,000
Net loss		$ (3,637,000)	$ (4,087,000)	$ (7,592,000)	$ (8,729,000)
Basic and diluted net loss per share (in dollars per share)	[1]	$ (0.41)	$ (0.46)	$ (0.85)	$ (0.98)
Shares used in computing basic and diluted net loss per share (in shares)		8,928	8,902	8,928	8,899
[1]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgicals one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ (3,637)	$ (4,087)	$ (7,592)	$ (8,729)
Changes in market value of investments:
Change in unrealized loss on short-term investments, net of tax	4	(9)	4	(6)
Comprehensive loss	$ (3,633)	$ (4,096)	$ (7,588)	$ (8,735)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating activities:
Net loss	$ (7,592)	$ (8,729)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	316	543
Amortization of premiums on marketable securities	12	106
Stock-based compensation expense	724	400
Non-cash interest expense	169	143
Changes in operating assets and liabilities:
Accounts receivable, net	(176)	(109)
Prepaid expenses and other current assets	210	89
Inventories	(442)	373
Accounts payable and other accrued liabilities	79	255
Deferred revenue	(51)
Accrued compensation	(157)	451
Net cash used in operating activities	(6,908)	(6,478)
Investing activities:
Purchases of property and equipment	(47)	(136)
Proceeds from maturities of investments	9,600	13,658
Purchases of investments	(1,168)	(8,927)
Net cash provided by investing activities	8,385	4,595
Net increase (decrease) in cash and cash equivalents	1,477	(1,883)
Cash and cash equivalents at beginning of period	3,626	8,264
Cash and cash equivalents at end of period	5,103	6,381
Supplemental disclosure of cash flow information:
Interest paid	$ 100	$ 100

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Organization Dextera Surgical Inc. (the “Company”) was incorporated in the state of Delaware on October 15, 1997, November 26, 2001, June 19, 2016, 5/80™ 5/80, 5 80 30 In January 2016, 510(k) 5/80 July 2016, 510(k) 5/80 5/80 510(k) 5/80, 5/80 55 200 5/80, 5/80. 120 The Company is also attempting to expand use of the MicroCutter 5/80 30 March 2016, 30 5/80 5/80 August 2013, 30 April 2014, 30 third 2014 January 2015, August 2015 30 5/80 5/80 Historically, the Company generated product revenues primarily from the sale of automated anastomotic systems; however, the Company started generating revenues from the commercial sales of the microcutter products since its introduction in Europe in December 2012, March 2014, December 31, 2016, $2.0 For the six December 31, 2016, $1.3 $0.8 $0.3 $0.1 $35,000 Need for Additional Capital Going Concern The Company has incurred cumulative net losses of $213.3 December 31, 2016, December 31, 2016, $5.8 $4.0 The Company believes that the existing cash, cash equivalents and short-term investments will be sufficient to meet its anticipated cash needs to enable it to conduct its business substantially as currently conducted for at least the next three August 2016, $4.0 ten $44.0 April 2014, July 2014 September 30, 2018. 7% $0.8 December 31, 2016. The Company does not agree with Century’s assertions as the Company believes that it had notified Century of the financing that occurred in April 2014 August 2016, December 31, 2016. ($0.7 December 31, 2016). $4.0 September 30, 2018, The Company may In order to satisfy its longer term liquidity requirements, the Company may third one may may may may The Company’s condensed consolidated financial statements have been prepared assuming that it will continue as a going concern. This assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Its continuation as a going concern is contingent upon its ability to generate revenue and cash flow to meet its obligations on a timely basis and its ability to raise financing. The Company’s plans will be adversely impacted if it fails to raise financing. However, there can be no assurance that the Company will be able to raise such funds. Failure to obtain future funding on acceptable terms would adversely affect its ability to fund operations and continues as a going concern. These matters raise substantial doubt about the ability of the Company to continue in existence as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended June 30, 2016, 10 October 12, 2016. Reverse Stock Split On February 16, 2016, one ten 89,344,777 8,934,452, February 17, 2016. $80,000 All shares of common stock, stock options, warrants to purchase common stock, the conversion rate of preferred stock and per share information presented in the condensed consolidated financial statements have been adjusted to reflect the Reverse Split on a retroactive basis for all periods presented and all share information is rounded down to the nearest whole share after reflecting the Reverse Split. Recently Issued Accounting Standards In August 2016, 2016 15, 230): 2016 15 December 15, 2017, In June 2016, 2016 13, 326): December 15, 2019, December 15, 2019. In May 2016, 2016 12, 606): may 2014 09, 2015 14). In April 2016, 2016 10, 606): 2014 09, 2015 14). In March 2016, 2016 09, Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting, December 15, 2016, In March 2016, 2016 08, 2014 09 606), December 15, 2017, 2019 July 1, 2018). In February 2016, 2016 02, Leases, 12 December 15, 2018. In January 2016, 2016 01, Recognition and Measurement of Financial Assets and Financial Liabilities 2016 01 December 15, 2017. In November 2015, 2015 17, 740): Balance Sheet Classification of Deferred Taxes one one 2015 17 December 15, 2016, 2017 July 1, 2016. may In July 2015, first December 15, 2016, December 15, 2017. In May 2014, 2014 09, 606): Revenue from Contracts with Customers 605, Revenue Recognition 2014 09 2014 09 may 2014 09 December 15, 2017, 2019 July 1, 2018). December 15, 2016. Use of Estimates The preparation of financial statements in conformity with GAAP generally requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Significant estimates include the valuation of inventory, measurement of stock based compensation, valuation of financial instruments and revenue recognition. Actual results could materially differ from these estimates. Revenue Recognition The Company recognizes revenue when four (1) (2) (3) (4) third The Company records product sales net of estimated product returns and discounts from the list prices for its products. The amounts of product returns and the discount amounts have not been material to date. The Company’s sales to distributors do not include price protection. Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved subject to satisfaction of all revenue recognition criteria at that time. Revenue generated from license fees and performing development services are recognized when they are earned and non-refundable upon receipt, over the period of performance, or upon incurrence of the related development expenses in accordance with contractual terms, based on the actual costs incurred to date plus overhead costs for certain project activities. Amounts paid but not yet earned on a project are recorded as deferred revenue until such time as performance is rendered or the related development expenses, plus overhead costs for certain project activities, are incurred. Inventories Inventories are recorded at the lower of cost or market on a first first may Risks and Uncertainties The Company depends upon a number of key suppliers, including single source suppliers, the loss of which would materially harm the Company’s business. Single source suppliers are relied upon for certain components and services used in manufacturing the Company’s products. The Company does not have long-term contracts with any of the suppliers; rather, purchase orders are submitted for each order. Because long-term contracts do not exist, none of the suppliers are required to provide the Company any guaranteed minimum quantities. Foreign Currency Translation The Company’s foreign operations are subject to exchange rate fluctuations and foreign currency costs. The functional currency of the German subsidiary is the United States dollar. Transactions and balances denominated in dollars are presented at their original amounts. Monetary assets and liabilities denominated in currencies other than the dollar are re-measured at the current exchange rate prevailing at the balance sheet date. All transaction gains or losses from the re-measurement of monetary assets and liabilities are included in the consolidated statements of operations within other income (expense).

Note 2 - Stockholders' Equity

Note 2 - Stockholders' Equity	6 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 2 Common Stock and Preferred Stock In April 2014, 3,737,500 $8.50 191,474 $85 10 9.98% 61 9.98% $44.6 June 30, 2014, $1.9 A one April 2014. Stock-Based Compensation Stock-based compensation expense related to employee and director share-based compensation plans, including stock options and restricted stock units, or RSUs, pursuant to Accounting Standards Codification, or ASC, 718 505 50, The Company selected the Black-Scholes option pricing model for determining the estimated fair value-based measurements of share-based awards. The use of the Black-Scholes model requires the use of assumptions including expected term, expected volatility, risk-free interest rate and expected dividends. The Company used the following assumptions in its fair value-based measurements: Three months ended Six months ended December 31, December 31, 2016 201 5 2016 201 5 Risk-free interest rate 1.25% – 1.98% 1.33 % 1.11% - 1.98% 0.71% - 1.50% Dividend yield — — — — Weighted-average expected term (in years) 4.80 – 4.83 4.98 4.80 - 4.83 4.24 - 4.98 Expected volatility 74.7% - 77.5% 67.4 % 74.7% - 77.5% 54.8% - 67.4% The Company estimates the expected life of options granted based on historical exercise and post-vest cancellation patterns, which the Company believes are representative of future behavior . The risk-free interest rate for the expected term of each option is based on a risk-free zero 718 $0.7 $0.4 six December 31, 2016 2015, The Company recorded stock-based compensation expenses for awards granted to non-employees under ASC 505 50 $0 $5,991 six December 31, 2016 2015, $0.7 December 31, 2016, 3.5 Included in the statement of operations are the following non-cash stock-based compensation expenses (in thousands): Three months ended Six months ended December 31, December 31, 2016 201 5 201 6 201 5 Cost of product sales $ 48 $ 17 $ 70 $ 35 Research and development 121 30 189 72 Selling, general and administrative 257 218 465 293 Total $ 426 $ 265 $ 724 $ 400

Note 3 - Net Loss Per Share

Note 3 - Net Loss Per Share	6 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 3 Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding for the period, and without consideration of potential common shares. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, plus dilutive potential common shares for the period determined using the treasury-stock method. For purposes of this calculation, options and warrants to purchase stock and unvested restricted stock awards are considered to be potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive. In the years the preferred stock is outstanding, the two 260 Earnings per Share two two two The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share data): Three months ended Six months ended December 31, December 31, 2016 2015 2016 2015 Numerator: Net loss $ (3,637 ) $ (4,087 ) $ (7,592 ) $ (8,729 ) Denominator: Denominator for basic and diluted net loss per share 8,928 8,902 8,928 8,899 Basic and diluted net loss per share $ (0.41 ) $ (0.46 ) $ (0.85 ) $ (0.98 ) The following table sets forth the outstanding securities not included in the diluted net loss per common share calculation as of December 31, 2016 2015, As of December 31, 201 6 201 5 Options to purchase common stock 1,538 939 Unvested restricted stock awards 64 53 Shares reserved for issuance upon conversion of Series A Preferred 1,915 1,915 Total 3,517 2,907

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	6 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 4 ASC 820, 820 three three Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Observable inputs other than quoted prices included in Level 1, Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company does not As of December 31, 2016 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 2,025 $ — $ — $ 2,025 Corporate debt securities — 982 — 982 Commercial paper — 600 — 600 Short-term investments: Corporate debt securities — 650 — 650 Total assets at fair value $ 2,025 $ 2,232 $ — $ 4,257 As of June 30, 201 6 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 3,029 $ — $ — $ 3,029 Short-term investments: Commercial paper — 999 — 999 Corporate debt securities — 8,091 — 8,091 Total assets at fair value $ 3,029 $ 9,090 $ — $ 12,119 Funds held in money market instruments are included in Level 1 Corporate debt securities and commercial papers are valued primarily using market prices comparable securities, bid/ask quotes, interest rate yields, and prepayment spreads and are included in Level 2. Cash balances of $1.5 December 31, 2016, $0.6 June 30, 2016, December 31, 2016, December 31, 2016, 3 See “Note 8 See “Note 7 L icense, D evelopment A nd C ommercialization A greements”

Note 5 - Available-for-sale Sec

Note 5 - Available-for-sale Securities	6 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	NOTE 5 Available–for-Sale Securities The Company held investments in marketable securities as of December 31, 2016, June 30, 2016, one one The Company’s investments consisted of the following (in thousands): As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: Corporate debt securities – Short-term $ 650 $ — $ — $ 650 Total $ 650 $ — $ — $ 650 As of June 30, 201 6 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: Commercial paper – Short-term $ 999 $ — $ — $ 999 Corporate debt securities – Short-term 8,095 — (4 ) 8,091 Total $ 9,094 $ — $ (4 ) $ 9,090 There are no gross unrealized losses at December 31, 2016. June 30, 2016, June 30, 2016 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt securities $ 8,091 $ (4 ) $ — $ — $ 8,091 $ (4 ) Total $ 8,091 $ (4 ) $ — $ — $ 8,091 $ (4 ) The Company reviews investments for other-than-temporary impairment. It was determined that unrealized losses at June 30, 2016,

Note 6 - Inventories

Note 6 - Inventories	6 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 6 Inventories consisted of the following (in thousands): December 31, 2016 June 30, 201 6 Raw materials $ 785 $ 698 Work in progress 284 133 Finished goods 436 232 Total $ 1,505 $ 1,063

Note 7 - Distribution, License,

Note 7 - Distribution, License, Development and Commercialization Agreements	6 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 7 Century On September 2, 2011, $4.0 September 30, 2016, two July 1, 2014. $2.0 September 30, 2011, $2.0 December 27, 2011. 5% September 30, 2018, $4.0 August 2016, $4.0 ten $44.0 April 2014, July 2014 September 30, 2018. 7% 0.8 December 31, 2016. 8 . In return for the loan commitment, the Company granted Century distribution rights to the Company’s planned microcutter product line in Japan, and a right of first August 2013, 30 April 2014, 30 third 2014 January 2015, August 2015, 30 5/80 5/80 Proceeds from the note and granting the distribution rights were allocated to the note based on its aggregate fair value of $2.4 18%, $1.6 first December 31, 2016. The Company’s distribution agreement with Century pertaining to the PAS-Port system, originally dated June 16, 2003, July 31, 2014. September 30, 2018, July 1, 2014, five July 31, 2019. 2011 $3.1 $2.6 $0.5 18%, $0.5 first As of December 31, 2016, June 30, 2016, $3.3 $3.1 $0.7 $0.9 For the six December 31, 2016 2015, 16% 30%, December 31, 2016, June 30, 2016, 10% 33%, Intuitive Surgical On August 16, 2010, $9.0 The Company determined that there were two August 16, 2010, may three $9.0 $1.0 two $9.0 $10.0 August 16, 2010, June 30, 2011, $1.0 may three three June 30, 2016, 2015 2014, $0, $0 $41,000, June 30, 2016 2015, no On December 31, 2015, August 2010, da Vinci one $2.0 August 16, 2018, December 31, 2015, June 30, 2016. may The feasibility evaluation allowed Intuitive Surgical six August 2016, 8 da Vinci Pursuant to the agreement, the Company will receive further funding for development of the cartridge and tooling as well as a unit-based royalty on commercial sales. The Company determined that there were two December 30, 2015; may two $2.0 two 3 $1.4 $2.0 December 30, 2015, three March 31, 2016, $0.6 may two two December 31, 2016, $1.5 December 31, 2016, $0.5 December 31, 2016, $0.1 Cook Incorporated In June 2007, September 2007 June 2009 one not six December 31, 2016 2015. $0.4 December 31, 2016, June 30, 2016. January 6, 2010,

Note 8 - Note Payable

Note 8 - Note Payable	6 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 8 In connection with the Distribution Agreement with Century (see Note 7), $4.0 June 30, 2012, July 1, 2014, two $2.0 September 30, 2011, $2.0 December 27, 2011. 5% March, June, September December September 30, 2018, $4.0 $2.1 In August 2016, $4.0 ten $44.0 April 2014, July 2014 September 30, 2018. 7% $0.8 December 31, 2016. The Company does not agree with Century’s assertions as the Company believes it had notified Century of the financing that occurred in April 2014 August 2016, December 31, 2016. ($0.7 December 31, 2016). As of December 31, 2016, June 30, 2016, $3.3 $3.1 $0.7 $0.9

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	6 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 9 COMMITMENTS AND CONTINGENCIES Operating Lease On November 11, 2010, August 31, 2018 three August 31, 2018, $0.1 December 31, 2016, June 30, 2016, Future minimum lease payments under the Company’s non-cancelable operating leases having initial terms of a year or more as of December 31, 2016, Fiscal year ending June 30, Operating Leases 2017 (remaining six months) $ 503 2018 1,032 2019 173 Total minimum lease payments $ 1,708

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Organization [Policy Text Block]	Organization Dextera Surgical Inc. (the “Company”) was incorporated in the state of Delaware on October 15, 1997, November 26, 2001, June 19, 2016, 5/80™ 5/80, 5 80 30 In January 2016, 510(k) 5/80 July 2016, 510(k) 5/80 5/80 510(k) 5/80, 5/80 55 200 5/80, 5/80. 120 The Company is also attempting to expand use of the MicroCutter 5/80 30 March 2016, 30 5/80 5/80 August 2013, 30 April 2014, 30 third 2014 January 2015, August 2015 30 5/80 5/80 Historically, the Company generated product revenues primarily from the sale of automated anastomotic systems; however, the Company started generating revenues from the commercial sales of the microcutter products since its introduction in Europe in December 2012, March 2014, December 31, 2016, $2.0 For the six December 31, 2016, $1.3 $0.8 $0.3 $0.1 $35,000
Liquidity [Policy Text Block]	Going Concern The Company has incurred cumulative net losses of $213.3 December 31, 2016, December 31, 2016, $5.8 $4.0 The Company believes that the existing cash, cash equivalents and short-term investments will be sufficient to meet its anticipated cash needs to enable it to conduct its business substantially as currently conducted for at least the next three August 2016, $4.0 ten $44.0 April 2014, July 2014 September 30, 2018. 7% $0.8 December 31, 2016. The Company does not agree with Century’s assertions as the Company believes that it had notified Century of the financing that occurred in April 2014 August 2016, December 31, 2016. ($0.7 December 31, 2016). $4.0 September 30, 2018, The Company may In order to satisfy its longer term liquidity requirements, the Company may third one may may may may The Company’s condensed consolidated financial statements have been prepared assuming that it will continue as a going concern. This assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Its continuation as a going concern is contingent upon its ability to generate revenue and cash flow to meet its obligations on a timely basis and its ability to raise financing. The Company’s plans will be adversely impacted if it fails to raise financing. However, there can be no assurance that the Company will be able to raise such funds. Failure to obtain future funding on acceptable terms would adversely affect its ability to fund operations and continues as a going concern. These matters raise substantial doubt about the ability of the Company to continue in existence as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
Basis of Presentation and Principles of Consolidation [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended June 30, 2016, 10 October 12, 2016.
Stockholders' Equity, Policy [Policy Text Block]	Reverse Stock Split On February 16, 2016, one ten 89,344,777 8,934,452, February 17, 2016. $80,000 All shares of common stock, stock options, warrants to purchase common stock, the conversion rate of preferred stock and per share information presented in the condensed consolidated financial statements have been adjusted to reflect the Reverse Split on a retroactive basis for all periods presented and all share information is rounded down to the nearest whole share after reflecting the Reverse Split.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards In August 2016, 2016 15, 230): 2016 15 December 15, 2017, In June 2016, 2016 13, 326): December 15, 2019, December 15, 2019. In May 2016, 2016 12, 606): may 2014 09, 2015 14). In April 2016, 2016 10, 606): 2014 09, 2015 14). In March 2016, 2016 09, Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting, December 15, 2016, In March 2016, 2016 08, 2014 09 606), December 15, 2017, 2019 July 1, 2018). In February 2016, 2016 02, Leases, 12 December 15, 2018. In January 2016, 2016 01, Recognition and Measurement of Financial Assets and Financial Liabilities 2016 01 December 15, 2017. In November 2015, 2015 17, 740): Balance Sheet Classification of Deferred Taxes one one 2015 17 December 15, 2016, 2017 July 1, 2016. may In July 2015, first December 15, 2016, December 15, 2017. In May 2014, 2014 09, 606): Revenue from Contracts with Customers 605, Revenue Recognition 2014 09 2014 09 may 2014 09 December 15, 2017, 2019 July 1, 2018). December 15, 2016.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP generally requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Significant estimates include the valuation of inventory, measurement of stock based compensation, valuation of financial instruments and revenue recognition. Actual results could materially differ from these estimates.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue when four (1) (2) (3) (4) third The Company records product sales net of estimated product returns and discounts from the list prices for its products. The amounts of product returns and the discount amounts have not been material to date. The Company’s sales to distributors do not include price protection. Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved subject to satisfaction of all revenue recognition criteria at that time. Revenue generated from license fees and performing development services are recognized when they are earned and non-refundable upon receipt, over the period of performance, or upon incurrence of the related development expenses in accordance with contractual terms, based on the actual costs incurred to date plus overhead costs for certain project activities. Amounts paid but not yet earned on a project are recorded as deferred revenue until such time as performance is rendered or the related development expenses, plus overhead costs for certain project activities, are incurred.
Inventory, Policy [Policy Text Block]	Inventories Inventories are recorded at the lower of cost or market on a first first may
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Risks and Uncertainties The Company depends upon a number of key suppliers, including single source suppliers, the loss of which would materially harm the Company’s business. Single source suppliers are relied upon for certain components and services used in manufacturing the Company’s products. The Company does not have long-term contracts with any of the suppliers; rather, purchase orders are submitted for each order. Because long-term contracts do not exist, none of the suppliers are required to provide the Company any guaranteed minimum quantities.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company’s foreign operations are subject to exchange rate fluctuations and foreign currency costs. The functional currency of the German subsidiary is the United States dollar. Transactions and balances denominated in dollars are presented at their original amounts. Monetary assets and liabilities denominated in currencies other than the dollar are re-measured at the current exchange rate prevailing at the balance sheet date. All transaction gains or losses from the re-measurement of monetary assets and liabilities are included in the consolidated statements of operations within other income (expense).

Note 2 - Stockholders' Equity (

Note 2 - Stockholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three months ended Six months ended December 31, December 31, 2016 201 5 2016 201 5 Risk-free interest rate 1.25% – 1.98% 1.33 % 1.11% - 1.98% 0.71% - 1.50% Dividend yield — — — — Weighted-average expected term (in years) 4.80 – 4.83 4.98 4.80 - 4.83 4.24 - 4.98 Expected volatility 74.7% - 77.5% 67.4 % 74.7% - 77.5% 54.8% - 67.4%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three months ended Six months ended December 31, December 31, 2016 201 5 201 6 201 5 Cost of product sales $ 48 $ 17 $ 70 $ 35 Research and development 121 30 189 72 Selling, general and administrative 257 218 465 293 Total $ 426 $ 265 $ 724 $ 400

Note 3 - Net Loss Per Share (Ta

Note 3 - Net Loss Per Share (Tables)	6 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three months ended Six months ended December 31, December 31, 2016 2015 2016 2015 Numerator: Net loss $ (3,637 ) $ (4,087 ) $ (7,592 ) $ (8,729 ) Denominator: Denominator for basic and diluted net loss per share 8,928 8,902 8,928 8,899 Basic and diluted net loss per share $ (0.41 ) $ (0.46 ) $ (0.85 ) $ (0.98 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of December 31, 201 6 201 5 Options to purchase common stock 1,538 939 Unvested restricted stock awards 64 53 Shares reserved for issuance upon conversion of Series A Preferred 1,915 1,915 Total 3,517 2,907

Note 4 - Fair Value Measureme19

Note 4 - Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2016
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	As of December 31, 2016 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 2,025 $ — $ — $ 2,025 Corporate debt securities — 982 — 982 Commercial paper — 600 — 600 Short-term investments: Corporate debt securities — 650 — 650 Total assets at fair value $ 2,025 $ 2,232 $ — $ 4,257 As of June 30, 201 6 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 3,029 $ — $ — $ 3,029 Short-term investments: Commercial paper — 999 — 999 Corporate debt securities — 8,091 — 8,091 Total assets at fair value $ 3,029 $ 9,090 $ — $ 12,119

Note 5 - Available-for-sale S20

Note 5 - Available-for-sale Securities (Tables)	6 Months Ended
	Dec. 31, 2016
Notes Tables
Available-for-sale Securities [Table Text Block]	As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: Corporate debt securities – Short-term $ 650 $ — $ — $ 650 Total $ 650 $ — $ — $ 650 As of June 30, 201 6 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: Commercial paper – Short-term $ 999 $ — $ — $ 999 Corporate debt securities – Short-term 8,095 — (4 ) 8,091 Total $ 9,094 $ — $ (4 ) $ 9,090
Schedule of Unrealized Loss on Investments [Table Text Block]	June 30, 2016 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt securities $ 8,091 $ (4 ) $ — $ — $ 8,091 $ (4 ) Total $ 8,091 $ (4 ) $ — $ — $ 8,091 $ (4 )

Note 6 - Inventories (Tables)

Note 6 - Inventories (Tables)	6 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2016 June 30, 201 6 Raw materials $ 785 $ 698 Work in progress 284 133 Finished goods 436 232 Total $ 1,505 $ 1,063

Note 9 - Commitments and Cont22

Note 9 - Commitments and Contingencies (Tables)	6 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Fiscal year ending June 30, Operating Leases 2017 (remaining six months) $ 503 2018 1,032 2019 173 Total minimum lease payments $ 1,708

Note 1 - Summary of Significa23

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Feb. 16, 2016shares	Apr. 30, 2014USD ($)	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)shares	Sep. 30, 2016	Aug. 31, 2016USD ($)	Jun. 30, 2016USD ($)shares	Feb. 17, 2016shares	Jul. 01, 2014USD ($)
Revenue, Net			$ 799,000	$ 700,000	$ 1,266,000	$ 1,455,000
License and Services Revenue			83,000		109,000
Royalty Revenue			21,000	$ 17,000	35,000	$ 35,000
Retained Earnings (Accumulated Deficit)			(213,288,000)		(213,288,000)		$ (213,288,000)			$ (205,696,000)
Cash, Cash Equivalents, and Short-term Investments			5,800,000		5,800,000		5,800,000
Long-term Debt, Gross			4,000,000		4,000,000		4,000,000
Proceeds from Issuance or Sale of Equity		$ 44,600,000
Interest Expense, Debt Penalties					800,000
Debt Instrument, Unamortized Discount			$ 700,000		$ 700,000		$ 700,000
Common Stock, Shares, Outstanding | shares	89,344,777		8,934,452		8,934,452		8,934,452			8,927,830	8,934,452
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10
Reverse Stock Split [Member] | Reclassification from Common Stock to Additional Paid-in Capital [Member]
Current Period Reclassification Adjustment					$ 80,000
Century Medical [Member]
Debt Instrument, Face Amount									$ 4,000,000
Debt Instrument, Unamortized Discount			$ 700,000		$ 700,000		$ 700,000					$ 2,100,000
Century Medical [Member] | Pro Forma [Member]
Debt Instrument, Penalty Rate			7.00%		7.00%		7.00%	7.00%
Interest Expense, Debt Penalties					$ 800,000
Microcutter Products [Member]
Revenue, Net					300,000		$ 2,000,000
Automated Anastomotic Systems [Member]
Revenue, Net					$ 800,000

Note 2 - Stockholders' Equity24

Note 2 - Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2014
Proceeds from Issuance or Sale of Equity	$ 44,600,000
Allocated Share-based Compensation Expense		$ 700,000	$ 400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 700,000		$ 700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				3 years 182 days
Non-employees [Member]
Allocated Share-based Compensation Expense				$ 0	$ 5,991
Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues	191,474
Share Price	$ 85
Convertible Preferred Stock, Shares Issued upon Conversion	10
Common Stock Ownership Threshold, Preferred Stock Conversion	9.98%
Dividends Payable						$ 1,900,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues	3,737,500
Share Price	$ 8.50

Note 2 - Stockholders' Equity -

Note 2 - Stockholders' Equity - Black-scholes Valuation Assumptions (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Risk-free interest rate		1.33%
Dividend yield	0.00%		0.00%	0.00%
Weighted-average expected term (in years) (Year)		4 years 357 days
Expected volatility		67.40%
Minimum [Member]
Risk-free interest rate	1.25%		1.11%	0.71%
Weighted-average expected term (in years) (Year)	4 years 292 days		4 years 292 days	4 years 87 days
Expected volatility	74.70%		74.70%	54.80%
Maximum [Member]
Risk-free interest rate	1.98%		1.98%	1.50%
Weighted-average expected term (in years) (Year)	4 years 302 days		4 years 302 days	4 years 357 days
Expected volatility	77.50%		77.50%	67.40%

Note 2 - Stockholders' Equity26

Note 2 - Stockholders' Equity - Non-cash Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Stock-based compensation expense	$ 426	$ 265	$ 724	$ 400
Cost of Sales [Member]
Stock-based compensation expense	48	17	70	35
Research and Development Expense [Member]
Stock-based compensation expense	121	30	189	72
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 257	$ 218	$ 465	$ 293

Note 3 - Net Loss Per Share - C

Note 3 - Net Loss Per Share - Computation of Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Numerator:
Net loss		$ (3,637)	$ (4,087)	$ (7,592)	$ (8,729)
Denominator:
Shares used in computing basic and diluted net loss per share (in shares)		8,928	8,902	8,928	8,899
Basic and diluted net loss per share (in dollars per share)	[1]	$ (0.41)	$ (0.46)	$ (0.85)	$ (0.98)
[1]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgicals one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.

Note 3 - Net Loss Per Share - A

Note 3 - Net Loss Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands	6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive securities excluded from the computation of earnings per share (in shares)	3,517	2,907
Employee Stock Option [Member]
Antidilutive securities excluded from the computation of earnings per share (in shares)	1,538	939
Restricted Stock [Member]
Antidilutive securities excluded from the computation of earnings per share (in shares)	64	53
Common Stock Shares Reserved for Future Issuance [Member]
Antidilutive securities excluded from the computation of earnings per share (in shares)	1,915	1,915

Note 4 - Fair Value Measureme29

Note 4 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Cash	$ 1,500	$ 600
Liabilities, Fair Value Disclosure, Recurring	$ 0

Note 4 - Fair Value Measureme30

Note 4 - Fair Value Measurements - Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Investments	$ 650	$ 9,090
Short-term Commercial Paper [Member]
Investments		999
Short-term Corporate Debt Securities [Member]
Investments	650	8,091
Fair Value, Measurements, Recurring [Member]
Total assets at fair value	4,257	12,119
Fair Value, Measurements, Recurring [Member] | Short-term Commercial Paper [Member]
Investments		999
Fair Value, Measurements, Recurring [Member] | Short-term Corporate Debt Securities [Member]
Investments	650	8,091
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Total assets at fair value	2,025	3,029
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Commercial Paper [Member]
Investments
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Corporate Debt Securities [Member]
Investments
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Total assets at fair value	2,232	9,090
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Commercial Paper [Member]
Investments		999
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Corporate Debt Securities [Member]
Investments	650	8,091
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Total assets at fair value
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Commercial Paper [Member]
Investments
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Corporate Debt Securities [Member]
Investments
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents	2,025	3,029
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents	2,025	3,029
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents
Corporate Debt Securities with Maturity Less than 90 Days [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents	982
Corporate Debt Securities with Maturity Less than 90 Days [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents
Corporate Debt Securities with Maturity Less than 90 Days [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents	982
Corporate Debt Securities with Maturity Less than 90 Days [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents	600
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents	600
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents

Note 5 - Available-for-sale S31

Note 5 - Available-for-sale Securities - Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Amortized Cost	$ 650	$ 9,094
Gross Unrealized Losses		(4)
Fair Value	650	9,090
Investments	650	9,090
Short-term Corporate Debt Securities [Member]
Amortized Cost	650	8,095
Gross Unrealized Losses		(4)
Fair Value	650	8,091
Investments	$ 650	8,091
Short-term Commercial Paper [Member]
Amortized Cost		999
Gross Unrealized Losses		0
Fair Value		999
Investments		$ 999

Note 5 - Available-for-sale S32

Note 5 - Available-for-sale Securities - Investment Securities in a Continuous Unrealized Loss Position (Details) $ in Thousands	Jun. 30, 2016USD ($)
Less than 12 months Fair Value	$ 8,091
Less than 12 months Gross Unrealized Losses	(4)
12 months or greater Fair Value
12 months or greater Gross Unrealized Losses
Total Fair Value	8,091
Total Gross Unrealized Losses	(4)
Corporate Debt Securities [Member]
Less than 12 months Fair Value	8,091
Less than 12 months Gross Unrealized Losses	(4)
12 months or greater Fair Value
12 months or greater Gross Unrealized Losses
Total Fair Value	8,091
Total Gross Unrealized Losses	$ (4)

Note 6 - Inventories - Summary

Note 6 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Raw materials	$ 785	$ 698
Work in progress	284	133
Finished goods	436	232
Total	$ 1,505	$ 1,063

Note 7 - Distribution, Licens34

Note 7 - Distribution, License, Development and Commercialization Agreements (Details Textual) - USD ($)	Dec. 31, 2015	Jul. 01, 2014	Dec. 27, 2011	Sep. 30, 2011	Sep. 02, 2011	Aug. 16, 2010	Apr. 30, 2014	Sep. 30, 2011	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2016	Sep. 30, 2016	Aug. 31, 2016	Jun. 30, 2012	Jun. 30, 2011
Proceeds from Issuance or Sale of Equity							$ 44,600,000
Interest Expense, Debt Penalties										$ 800,000
Debt Instrument, Unamortized Discount										700,000					$ 700,000
Notes Payable, Noncurrent										3,293,000		$ 3,124,000			3,293,000
Deferred Revenue, Noncurrent										2,384,000		2,499,000			2,384,000
Deferred Revenue, Current										$ 633,000		569,000			$ 633,000
Century Medical [Member] | Sales Revenue, Net [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage										16.00%	30.00%
Century Medical [Member] | Accounts Receivable [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage										10.00%					33.00%
Intuitive Surgical [Member] | Initial Licensing Agreement [Member]
Deferred Revenue												0	$ 0
Licenses Revenue						$ 9,000,000						0	$ 0	$ 41,000
Common Stock Premium						1,000,000
Noncash or Part Noncash Divestiture, Amount of Consideration Received						$ 10,000,000
Deferred Revenue, Noncurrent																			$ 1,000,000
Intuitive Surgical [Member] | Amended Licensing Agreement [Member]
Licenses Revenue										$ 1,500,000
Proceeds from License Fees Received	$ 2,000,000
Deferred Revenue, Current										500,000					$ 500,000
Intuitive Surgical [Member] | Amended Licensing Agreement [Member] | Patented Technology [Member]
Proceeds from License Fees Received	$ 1,400,000
Intuitive Surgical [Member] | Amended Licensing Agreement [Member] | Developed Technology Rights [Member]
Proceeds from License Fees Received									$ 600,000
Intuitive Surgical [Member] | Joint Development Program [Member]
Licenses Revenue										100,000
Cook Incorporated [Member]
Licenses Revenue										0	$ 0
Deferred Revenue, Current										400,000		400,000			400,000
Century Medical [Member]
Debt Instrument, Face Amount																	$ 4,000,000
Proceeds from Secured Notes Payable			$ 2,000,000	$ 2,000,000				$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Notes Payable, Fair Value Disclosure		$ 2,600,000			$ 2,400,000
Debt Instrument, Unamortized Discount		$ 2,100,000								$ 700,000					$ 700,000
Distribution Agreement Term of Extension		5 years
Notes Payable		$ 3,100,000
Century Medical [Member] | Pro Forma [Member]
Debt Instrument, Penalty Rate										7.00%					7.00%	7.00%
Interest Expense, Debt Penalties										$ 800,000
Century Medical [Member] | Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount					$ 4,000,000													$ 4,000,000
Debt Instrument, Interest Rate, Stated Percentage					5.00%
Fair Value Inputs, Discount Rate		18.00%			18.00%
Debt Instrument, Unamortized Discount		$ 500,000			$ 1,600,000
Deferred Revenue		$ 500,000
Notes Payable, Noncurrent										3,300,000		3,100,000			$ 3,300,000
Debt Issuance Costs, Line of Credit Arrangements, Net										$ 700,000		$ 900,000			$ 700,000

Note 8 - Note Payable (Details

Note 8 - Note Payable (Details Textual) - USD ($)	Dec. 27, 2011	Sep. 30, 2011	Apr. 30, 2014	Sep. 30, 2011	Dec. 31, 2016	Sep. 30, 2016	Aug. 31, 2016	Jun. 30, 2016	Jul. 01, 2014	Jun. 30, 2012	Sep. 02, 2011
Debt Instrument, Unamortized Discount					$ 700,000
Proceeds from Issuance or Sale of Equity			$ 44,600,000
Interest Expense, Debt Penalties					800,000
Notes Payable, Noncurrent					3,293,000			$ 3,124,000
Century Medical [Member]
Debt Instrument, Face Amount							$ 4,000,000
Proceeds from Secured Notes Payable	$ 2,000,000	$ 2,000,000		$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage									5.00%
Debt Instrument, Unamortized Discount					$ 700,000				$ 2,100,000
Century Medical [Member] | Pro Forma [Member]
Debt Instrument, Penalty Rate					7.00%	7.00%
Interest Expense, Debt Penalties					$ 800,000
Century Medical [Member] | Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount										$ 4,000,000	$ 4,000,000
Debt Instrument, Interest Rate, Stated Percentage											5.00%
Debt Instrument, Unamortized Discount									$ 500,000		$ 1,600,000
Notes Payable, Noncurrent					3,300,000			3,100,000
Debt Issuance Costs, Line of Credit Arrangements, Net					$ 700,000			$ 900,000

Note 9 - Commitments and Cont36

Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Restricted Cash and Cash Equivalents	$ 104	$ 104
Restricted Cash, Letter of Credit [Member]
Restricted Cash and Cash Equivalents	$ 100	$ 100

Note 9 - Commitments and Cont37

Note 9 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2016USD ($)
2017 (remaining six months)	$ 503
2,018	1,032
2,019	173
Total minimum lease payments	$ 1,708